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Background/aim: It is known that the presence of fragmented QRS (fQRS) on electrocardiography (ECG) is associated with
cardiovascular events. The aim of this study was the evaluation of fQRS formation and its relationship with the left ventricular
hypertrophy (LVH) parameters in acromegaly patients.
Materials and methods: In total, 47 previously diagnosed with non-hypertensive acromegaly patients and 48 control subjects were
included in the study. ECG and transthoracic echocardiography (TTE) were performed for each participant. Acromegaly patients were
divided into two groups according to the fQRS formation on the ECG. Left ventricular wall thicknesses, and left atrial diameter (LAD),
left ventricular mass (LVM), left ventricular mass index (LVMi), and relative wall thickness (RWT) were obtained.
Results: In control group 5 (10.4%) and in acromegaly group 17 (36.2%) patients had fQRS on ECG (p = 0.003). LAD [36.0 (34.0–38.0)
vs. 38.0 (35.0–41.0) mm, p < 0.001], LVM [155.27 ± 27.00 vs. 173.0 (153.0–235.0) g, p < 0.001], LVMi [83.12 ± 13.19 vs. 92.0 (83.0–118.0)
g/m², p < 0.001] and RWT [0.39 ± 0.03 vs. 0.43 (0.41–0.45), p = 0.001] were significantly higher in patients with acromegaly. Disease
duration was significantly higher (11.59 ± 1.3 vs. 8.2 ± 1.8 years, p < 0.001) in the fQRS (+) group. LAD [41.0 (39.0–42.5) vs. 37.0 (34.7–
38.0) mm, p < 0.001], LVM [219.0 (160.5–254.5) vs. 164.0 (153.0–188.0) g, p = 0.017], LVMi [117.0 (92.5–128.5) vs. 86.0 (82.0–100.2)
g/m², p = 0.013] and RWT [0.44 (0.42–0.49) vs. 0.43 (0.40–0.44), p = 0.037] were significantly higher in fQSR (+) acromegaly patients.
In multivariate logistic regression analysis, disease duration (odds ratio: 10.05, 95% CI: 1.099–92.012, p = 0.041) and LAD (odds ratio:
2.19, 95% CI: 1.030–4.660, p = 0.042) were found to be the independent predictors of fQRS formation.
Conclusion: The results of our study revealed that fQRS (+) acromegaly patients had increased LVH parameters compared to fQRS (-)
patients.
Key words: Acromegaly, fragmented QRS, left ventricular hypertrophy, left ventricular mass

1. Introduction
Acromegaly is a rare, slowly progressive disease and
cardiovascular complications are the most common
cause of mortality in these patients [1–3]. The aetiological
cause in the majority of patients is growth hormone (GH)
secreting pituitary adenoma [4]. As the GH level increases,
the insulin-like growth factor-1 (IGF-1) level also
increases, leading to IGF-1 receptor activation in cardiac
myocytes [5]. mRNA expression increases in sarcomeric
proteins, and a subsequent increase in cardiac contractility
is seen before hypertrophy and myocardial fibrosis develop
[6–9]. Studies have shown that left ventricular mass
(LVM) and cardiac wall thickness increase in patients with
acromegaly [10–12]. Approximately 16% of patients have

cardiac hypertrophy at the time of diagnosis [13]. The
standard method used in the evaluation of left ventricular
hypertrophy (LVH) is transthoracic echocardiography
(TTE). Generally, left ventricular internal dimensions
and wall thicknesses are considered when evaluating LVH
with TTE. It is also stated that it is more appropriate to
use left ventricular mass index (LVMi) to standardize the
effect of body size when evaluating LVH in patients with
acromegaly [14,15]. LVH is a component of acromegalic
cardiomyopathy, which is associated with disease
duration, indicative of increased chronic GH/IGF-1
exposure [9]. Detailed evaluation of LVH using different
parameters with TTE may be more useful in determining
the cardiovascular prognosis.

* Correspondence: muhammet_dural@hotmail.com

This work is licensed under a Creative Commons Attribution 4.0 International License.

2437

DURAL et al. / Turk J Med Sci
Fragmented QRS (fQRS), which is associated with
myocardial scar tissue, defined as the presence of an
additional R wave (R’), R wave or the S wave notching, or
the presence of more than one R’ wave in two consecutive
leads in electrocardiography (ECG) [16]. All-cause
mortality and cardiac events were found to be associated
with the presence of fQRS in coronary artery disease
(CAD) patients [17–20]. There are limited data about
the relationship between the presence of fQRS in ECG
and acromegalic cardiomyopathy. In a recent study, fQRS
was found to be associated with impaired left ventricular
diastolic functions in acromegaly patients [21]. However,
there are no studies that have assessed the association
between fQRS and LVH parameters such as LVM, LVMi,
and relative wall thickness in patients with acromegaly.
As LVH progresses, interstitial fibrosis develops and a
deterioration in diastolic and even systolic functions can
gradually be seen. Therefore, fQRS, which has been shown
to be related to scar tissue, may be associated with LVH
in these patients. It suggests that acromegaly patients
with LVH may have a higher risk of developing poor
cardiovascular outcomes if fQRS is also present. In this
study, we aimed to evaluate the presence of fQRS and its
relationship with LVH parameters in acromegaly patients.
Revealing this relationship may be directive in the followup and treatment of acromegaly patients.
2. Material and methods
2.1. Study population
A total of 97 patients previously diagnosed with
acromegaly in accordance with the American Association
of Clinical Endocrinologists (AACE) revised criteria
of acromegaly diagnosis who applied to the outpatient
clinic of Endocrinology Department between November
2018 and December 2019 were included in the study
[22]. ECG and TTE were performed for each patient.
Those with hypertension (HT), CAD, severe valvular
heart disease, chronic infectious disease, autoimmune
disease, renal and/or hepatic failure and patients taking
any medication like statins, beta blockers and/or reninangiotensin-aldosterone system blockers were excluded
from the study. Therefore, the study population included
a total of 47 acromegaly patients and 48 sex-, body mass
index (BMI)-, and age-matched subjects. Firstly, the
patient group was compared with the control subjects.
Then, the patient population was divided into two groups
according to the presence or absence of fQRS on ECG.
A detailed cardiovascular and systemic examination was
performed in all subjects, and demographic data and
anthropometric measures including weight, height, and
BMI were recorded. Biochemical measurements fasting
blood glucose, total cholesterol, low-density lipoprotein
(LDL) cholesterol, serum creatinine, haemoglobin, serum

2438

growth hormone (GH), insulin like growth factor 1 (IGF1) were obtained from all patients with acromegaly. Disease
activity was assessed as indicated in the guidelines and
those with active acromegaly were identified [23]. After an
oral glucose tolerance test (OGTT) (75 g of glucose orally
followed by GH measurements every 30 min for 120 min),
serum GH measurements were performed previously in
every patient at the time of the first diagnosis. The Local
Ethics Committee of our institution approved the study
protocol.
2.1. Electrocardiography
Two blinded independent cardiologists evaluated the
twelve-lead ECGs (filter range, 0.15–100 Hz; AC filter, 50
Hz, 25 mm/s, 10 mm/mV). If there was any discrepancy
between the measurements of the two readers, ECGs
were examined by a third independent reviewer. All
ECGs were scanned and a more detailed analysis was
done on a personal computer with × 400% magnification.
Fragmented QRS is characterised by the presence of an
additional R wave (R’), R wave or the S wave notching, or
the presence of more than one R’ wave in two consecutive
leads (Figure 1) [16].
2.2. Echocardiography
As in ECG examination, TTEs were performed by two
blinded independent cardiologists by using Vivid S5 with
the GE 3S-RS Probe (GE Healthcare). Measurements of
the left ventricular internal dimensions, wall thicknesses,
and left atrial diameter (LAD) were obtained using linear
measurements in para-sternal long-axis view images
according to the recommendations of the American Society
of Echocardiography [24]. Relative wall thickness (RWT)
was calculated as 2 times the left ventricular posterior
wall thickness (PWT) divided by the left ventricular enddiastolic diameter (LVEDD) [25]. Left ventricular ejection
fraction (LVEF) was measured by using the modified
Simpson method (biplane method of disks). LVM was
calculated using the formula of the American Society of
Echocardiography (ASA) modiﬁed by Devereux et al.
[26]. According to the body surface area (BSA), LVMi was
calculated.
2.3. Statistical analysis
The distribution of each continuous variable was tested for
normality using the Shapiro–Wilk test and is expressed as
mean +/- standard deviation (SD). Normally distributed
variables were analyzed using the student t-test. Variables
with a skewed distribution are expressed as median value
[interquartile range (IQR)]. Nonnormally distributed
variables were analyzed using the Mann–Whitney U test.
The categorical variables are expressed in frequencies
and percentages. The Pearson’s Chi-square test was used
to compare categorical variables. Multiple binary logistic
regression analysis was used to define the independent
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Figure 1. Demonstration of a fQRS (+) acromegalic patient’s ECG. (Black arrows indicate fragmentation).

predictors of fQRS. P values < 0.05 were considered
statistically significant. All analyses were performed using
the SPSS v: 24.0 software (SPSS Inc., Chicago, IL, USA).
3. Results
There was no significant difference in basal characteristics
such as age (53.17 ± 13.26 vs. 51.21 ± 12.49 years, p = 0.462),
sex (56.3% vs. 51.1% female, p = 0.612), BMI (27.06 ± 3.1
vs. 28.55 ± 4.0 kg/m², p = 0.052) or the number of patients
with diabetes mellitus (DM) [7 (14.6%) vs. 8 (17.0%), p =
0.745] between the control group and acromegaly patients.
Mean disease duration was 9.43 ± 2.3 years in acromegaly
patients. Also, LVEF [65.0 (63.0–67.0) vs. 65.0 (60.0–68.0)
%, p = 0.460] and LVEDD [47.39 ± 2.74 vs. 47.0 (46.0–
49.0) mm, p = 0.126] were similar between the groups. On
the other hand, LAD [36.0 (34.0–38.0) vs. 38.0 (35.0–41.0)
mm, p < 0.001], interventricular septum thickness (IVST)
[10.0 (9.0–10.0) vs. 10.0 (10.0–12.0) mm, p < 0.001], PWT
[9.0 (9.0–10.0) vs. 10.0 (10.0–11.0) mm, p < 0.001], LVM
[155.27 ± 27.00 vs. 173.0 (153.0–235.0) g, p < 0.001], LVMi
[83.12 ± 13.19 vs. 92.0 (83.0–118.0) g/m², p < 0.001] and
RWT [0.39 ± 0.03 vs. 0.43 (0.41–0.45), p = 0.001] were
significantly higher in acromegaly group. In control group
5 (10.4%) and in acromegaly group 17 (36.2%) patients
had fQRS on ECG (p = 0.003). Baseline characteristics of
the control group and the acromegaly patients were shown
in Table 1.
Age (54.00 ± 12.77 vs. 49.63 ± 12.27 years, p = 0.254),
sex (47.1% vs. 53.3 female, p = 0.679), BMI (29.2 ± 2.52
vs. 28.17 ± 4.62 kg/m², p = 0.177), the number of patients
with DM [4 (23.5%) vs. 4 (13.3%), p = 0.371] and active
acromegaly patients [5 (29.4%) vs. 9 (30.0%), p = 0.966]
were similar between fQRS (+) and fQRS (-) groups.
Disease duration was significantly higher (11.59 ± 1.3 vs.
8.2 ± 1.8 years, p < 0.001) in the fQRS (+) group (Figure
2A). Median serum IGF-1 [208.0 (166.5–372.0) vs. 219.5
(149.2–536) ng/mL, p = 0.599] and GH levels [2.18 (0.78–
12.06) vs. 2.13 (1.16–5.24) ng/mL, p = 0.185] were similar

between the groups. Also, there is no significant difference
in LVEF [65.0 (62.0–68.0) vs. 67.0 (60.0–68.0) %, p =
0.595] and LVEDD [48.0 (45.5–51.0) vs. 47.0 (45.7–48.2)
mm, p = 0.440] between fQRS (+) and fQRS (-) patients,
while LAD [41.0 (39.0–42.5) vs. 37.0 (34.7–38.0) mm, p
< 0.001], IVST [12.0 (10.5–13.0) vs. 10.0 (10.0–11.0) mm,
p < 0.001], PWT [11.0 (10.0–12.0) vs. 10.0 (10.0–10.1)
mm, p < 0.001], LVM [219.0 (160.5–254.5) vs. 164.0
(153.0-188.0) g, p = 0.017], LVMi [117.0 (92.5–128.5) vs.
86.0 (82.0–100.2) g/m², p = 0.013] and RWT [0.44 (0.42–
0.49) vs. 0.43 (0.40–0.44), p = 0.037] were significantly
higher in fQSR (+) acromegaly patients (Figures 2B
and 2C). A comparison of the clinical, laboratory and
echocardiographic parameters of the fQRS (+) and fQRS
(-) acromegaly patients is illustrated in Table 2.
The predictors of fQRS formation were assessed by
univariate and multivariate logistic regression analyses. In
univariate analysis, disease duration (odds ratio: 4.60, 95%
CI: 1.802–11.745, p = 0.001), LAD (odds ratio: 1.62, 95%
CI: 1.188–2.217, p = 0.002), IVST (odds ratio: 2.56, 95% CI:
1.397–4.714, p = 0.002), PWT (odds ratio: 4.74, 95% CI:
1.766–12.706, p = 0.002), LVM (odds ratio: 1.01, 95% CI:
1.001–1.025, p = 0.040) and LVMi (odds ratio: 1.03, 95%
CI: 1.003–1.058, p = 0.031) were significantly associated
with fQRS. Disease duration, LAD, IVST, PWT, and LVMi
were included in multivariate logistic regression analysis.
Disease duration (odds ratio: 10.05, 95% CI: 1.099–92.012,
p = 0.041) and LAD (odds ratio: 2.19, 95% CI: 1.030–4.660,
p = 0.042) were found to be the independent predictors of
fQRS formation.
4. Discussion
In this study, the relationship between LVH, which is one
of the most basic findings of acromegalic cardiomyopathy
and fQRS, one of the important findings of myocardial
scar tissue, was investigated. The main findings of our
study were (i) fQRS was more common in patients with
acromegaly than in the control group; (ii) LVH parameters
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Table 1. Baseline characteristics of the study groups.
Control group
(n = 48)

Acromegaly
(n = 47)

p

Age, years

53.17 ± 13.26

51.21 ± 12.49

0.462

Body mass index, kg/m²

27.06 ± 3.1

28.55 ± 4.0

0.052

Female

27 (56.3%)

24 (51.1%)

Male

21 (43.7%)

23(48.9%)

0.612

Diabetes mellitus

7 (14.6%)

8 (17.0%)

0.745

Disease duration, years

-

9.43 ± 2.3

-

Serum IGF (ng/mL)

-

211.0 (160.0–444.0) -

Serum GH (ng/mL)

-

2.18 (0.96–5.90)

-

Serum creatinin (mg/dL)

0.80 ± 0.16

0.78 ± 0.15

0.536

Hemoglobin (g/d)

13.83 ± 1.31

13.57 ± 1.55

0.379

LDL-cholestrol (mg/dL)

122.34 ± 32.87

131.58 ± 28.69

0.158

Left ventricular ejection fraction, %

65.0 (63.0–67.0)

65.0 (60.0–68.0)

0.460

Left ventricular end-diastolic diameter, mm

47.39 ± 2.74

47.0 (46.0–49.0)

0.126

Left atrial diameter, mm

36.0 (34.0–38.0)

38.0 (35.0–41.0)

<0.001

Interventricular septum thickness, mm

10.0 (9.0–10.0)

10.0 (10.0–12.0)

<0.001

Left ventricular posterior wall thickness, mm

9.0 (9.0–10.0)

10.0 (10.0–11.0)

<0.001

Left ventricular mass, g

155.27 ± 27.00

173.0 (153.0–235.0) <0.001

Left ventricular mass index, g/m²

83.12 ± 13.19

92.0 (83.0–118.0)

<0.001

Relative wall thickness

0.39 ± 0.03

0.43 (0.41–0.45)

0.001

Fragmented QRS

5 (10.4%)

17 (36.2%)

0.003

Parameters

Sex, n (%)

GH: Growth hormone, IGF: Insulin-like growth factor, LDL: Low density lipoprotein
Note: The values are presented as mean+/-SD or median (min-max) and n (%).

were higher in acromegaly patients than in the control
group; (iii) disease duration and LVH parameters were
higher in fQRS (+) acromegalic patients than in fQRS (-)
individuals; and (iv) disease duration and LAD were the
independent predictors of the fQRS formation.
With cardiac magnetic resonance imaging, fQRS has
been shown to be associated with scar tissue in many
cardiac diseases [27–30]. In patients with acromegaly,
chronic excess of GH and IGF-1 secretion causes
biventricular concentric hypertrophy and then interstitial
fibrosis develops, which is accompanied by increased
extracellular collagen deposition, lympho-mononuclear
infiltrations, and myofibrillar derangement [31–33]. Due
to these areas of fibrosis, these patients are expected to
have a higher rate of fQRS formation on ECG than healthy
individuals. Indeed, in our study, fQRS formation was
higher in patients with acromegaly than in the control
group.
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The most important factor that determines the
prognosis in patients with acromegaly is cardiac
involvement because approximately 60% of these
patients die due to cardiovascular diseases [3]. Initially,
biventricular hypertrophy develops, and later diastolic and
systolic functions are impaired [34]. It has been shown in
many studies that LVM is associated with adverse cardiac
outcomes [35,36]. LVH is seen in approximately 16% of
patients with acromegaly [13]. When evaluating LVH,
not only wall thicknesses, but also LVM and even LVMi
should be taken into consideration. Therefore, LVM,
LVMi and RWT parameters were evaluated in addition to
left ventricular wall thicknesses in our study. We showed
that LVM, LVMi, and RWT were significantly higher in
acromegaly patients than in the control group, besides left
ventricular wall thicknesses.
In our study, we analysed patients with acromegaly by
dividing them into two groups based on the presence of
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250.00

p < 0.001

A

12.00

p = 0.013

B

200.00

10.00

LVMi

Disease Duration

14.00

8.00

150.00
100.00

6.00
4.00

50.00
fQRS (-)

fQRS (+)
55.00

LAD

50.00

fQRS (-)

fQRS (+)

p < 0.001

C

45.00
40.00
35.00
30.00
fQRS (-)

fQRS (+)

Figure 2. Disease duration, LVMi and LAD were significantly higher in fQRS (+) acromegalic patients compared to fQRS (-). (LAD
left atrial diameter, LMVi left ventricular mass index).

fQRS. We found that disease duration was significantly longer in the fQRS (+) group. Chronic exposure to excess GH
and IGF-1 causes interstitial fibrosis in the myocardium [31]. Therefore, more fibrosis will occur in patients with longer
disease duration. As a result, fQRS will also be more likely to occur in patients with longer disease duration. Also, the
LVH parameters such as IVST, PWT, LVM, LVMi, and RWT were found to be significantly higher in fQRS (+) acromegaly
patients than in fQRS (-) individuals. It has been shown in many studies that LVM is a predictor of cardiovascular disease
[35,37]. In a previous study, 15 nonhypertensive acromegaly patients were compared with healthy control subjects and it
was found that acromegaly patients had increased LVMi, RWT and impaired diastolic functions [38]. Also, with treatment,
it was shown that both LVH parameters regressed and diastolic functions improved [38]. The regression in LVH and the
improvement in myocardial function together with treatment shows the relationship between them. The fact that LVH
parameters were increased in acromegaly patients with fQRS (+) in our study may indicate that these patients have more
advanced acromegalic cardiomyopathy. Dereli et al.[21] evaluated fQRS frequency and LV functions in 60 acromegaly
patients in their study. As in our study, it was found that the disease duration was higher in the group with fQRS (+)
[21]. Those with fQRS (+) have been shown to have a greater impairment in LV function parameters such as E\A ratio, E’
velocity, E/E’ ratio, isovolumic relaxation time, and myocardial performance index (MPI) [21]. They also found that fQRS
is an independent predictor of MPI associated with LV dysfunction [21]. As a result, the researchers stated that fQRS may
be an indicator of acromegalic cardiomyopathy [21]. Differently, in our study, the relationship between LVH parameters
and fQRS was evaluated and patients with HT were excluded. Our results are supportive and complementary to previous
studies. Increased hypertrophy means increased fibrosis and scar tissue, and, in this case, fQRS can be thought to occur
more often. In addition, we found that acromegalic patients with fQRS (+) had a larger left atrium than those with fQRS (-).
In the multivariate regression analysis, one of the independent predictors of fQRS was the LAD. Atrial dilatation, which is a
sign of left atrial remodeling and diastolic dysfunction, has been shown to be associated with many cardiovascular diseases
such as atrial fibrillation and heart failure [39,40]. Therefore, those with fQRS may have greater myocardial dysfunction,
and these patients should be followed more closely to prevent the development of advanced acromeglic cardiomyopathy.
In fQRS (+) acromegalic patients, using speckle tracking echocardiography and cardiac magnetic resonance imaging
techniques can provide additional benefits in follow-up.
Our study is the first study assessing the relationship between the presence of fQRS and its relationship between the
LVH parameters in non-hypertensive acromegaly patients. However, our study has several limitations. This is a single
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Table 2. Clinical, laboratory and echocardiographic parameters of the acromegaly patients.
fQRS (+)
(n:17, 36.2%)

fQRS (-)
(n:30, 63.8%)

P

54.00 ± 12.77

49.63±12.27

0.254

Female

8 (47.1%)

16 (53.3%)

Male

9 (52.9%)

14 (46.7%)

0.679

Body mass index , kg/m²

29.2 ± 2.52

28.17 ± 4.62

0.177

Diabetes mellitus

4 (23.5%)

4 (13.3%)

0.371

Disease duration, years

11.59 ± 1.3

8.2 ± 1.8

<0.001

Serum IGF (ng/mL)

208.0 (166.5–372.0)

219.5 (149.2–536)

0.599

Serum GH (ng/mL)

2.18 (0.78–12.06)

2.13 (1.16–5.24)

0.185

Active acromgaly n (%)

5 (29.4%)

9 (30.0%)

0.966

Serum creatinin (mg/dL)

0.81 ± 0.16

0.76 ± 0.15

0.311

Hemoglobin (g/dL)

13.39 ± 1.55

13.67 ± 1.56

0.555

LDL-cholestrol (mg/dL)

134.47 ± 34.73

129.89 ± 25.02

0.607

Left ventricular ejection fraction, %

65.0 (62.0–68.0)

67.0 (60.0–68.0)

0.595

Left ventricular end-diastolic diameter,mm

48.0 (45.5–51.0)

47.0 (45.7–48.2)

0.440

Left atrial diameter, mm

41.0 (39.0–42.5)

37.0 (34.7–38.0)

<0.001

Interventricular septum thickness, mm

12.0 (10.5–13.0)

10.0 (10.0–11.0)

<0.001

Left ventricular posterior wall thickness, mm

11.0 (10.0–12.0)

10.0 (10.0–10.1)

<0.001

Left ventricular mass, g

219.0 (160.5–254.5)

164.0 (153.0–188.0)

0.017

Left ventricular mass index, g/m²

117.0 (92.5–128.5)

86.0 (82.0–100.2)

0.013

Relative wall thickness

0.44 (0.42–0.49)

0.43 (0.40–0.44)

0.037

Parameters
Age (years)
Sex, n (%)

GH: Growth hormone, IGF: Insulin-like growth factor, LDL: Low density lipoprotein
Note: The values are presented as mean+/-SD or median (min-max) and n (%).

center, cross sectional study and the number of patients in
the study is relatively small. Since LVH parameters were
evaluated, only non-hypertensive patients were included
in the study. In addition, more advanced techniques
such as speckle tracking echocardiography and cardiac
magnetic resonance imaging to evaluate the myocardial
functions and extent of scar tissue could be used. Also, the
lack of long-term follow-up in order to assess the clinical
significance of fQRS formation in acromegaly patients was
the other limitation of our study. Large scale, prospective,
long-term studies are needed to clarify the clinical
outcomes of fQRS formation in acromegalic patients.
5. Conclusion
In conclusion, we showed that fQRS (+) acromegaly
patients had increased LVH parameters and LAD than
fQRS (-) individuals. Disease duration and LAD were the
independent predictors of fQRS formation. Therefore,
fQRS (+) acromegaly patients should be followed more
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closely for acromegalic cardiomyopathy and cardiovascular
diseases.
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